Renew Biopharma, Inc.

Renew Biopharma, Inc. is a biotechnology startup with a focus on drug discovery to treat neuroinflammatory conditions. The company has developed a proprietary enzymatic platform through synthetic biology, allowing for the creation of a diverse pipeline of therapeutic molecules, specifically targeting neuroinflammation pathologies. With a keen interest in treating Traumatic Brain Injury (TBI), an area where there is currently no FDA-approved drug treatment available, Renew is pioneering a potentially groundbreaking solution. Renew's approach stands out due to its use of enzymatic chemistry processes, which contrast starkly with the traditional medicinal chemistry employed by major pharmaceutical companies. The enzymatic reactions employed by Renew are highly efficient and scalable, offering a promising new pathway for the development of therapeutic derivatives. The company's platform for creating therapeutic derivatives is protected by a robust IP portfolio, ensuring a competitive edge in the market. As of now, Renew Biopharma, Inc. was founded in 2017, and while there is no record available for its last investment, the company's novel approach to drug discovery and its specific focus on addressing a critical unmet medical need make it an intriguing prospect for potential investors in the biotechnology, healthcare, and pharmaceutical industries. With its headquarters in the United States, Renew's innovative methods and focus on addressing unmet medical needs positions them as a potential disruptor in the field of neuro-therapeutics.